Barker Brettell Sweden AB

A biostimulator (100) includes a housing (302) having a longitudinal axis (304) and containing an electronics compartment (306). The biostimulator (100) includes a fixation element mount (307) mounted on the housing (302). The biostimulator (100) includes a fixation element (106) mounted on the fixation element mount (307). The fixation element (106) includes a helical wire (320) extending helically about the longitudinal axis (304). The helical wire (304) tapers inward from a proximal turn (402) to a distal tip (322).

A system (1) for determining intravascular partial pressure of carbon dioxide (pCO₂) comprises an intravascular oxygen tension (pO₂) sensor (10) configured to measure pO₂ in a subject, an oxygen saturation (SO₂) sensor (20) configured to measure sO₂ in the subject, an intravascular pH sensor (30) configured to measure pH in blood of the subject and a temperature sensor (40) configured to measure temperature of the subject. The system (1) also comprises a processor (50) and a memory (60) coupled to the processor (50) and comprising instructions executable by the processor (50) to cause the processor (50) to determine intravascular pCO₂ for the subject based on the measured pO₂, SO₂, pH and temperature.

A biostimulator (100) includes a housing (302) having a longitudinal axis (304) and containing an electronics compartment (306). A fixation element mount (311) is mounted on the housing (302) and a fixation element (106) is mounted on the fixation element mount (311). The fixation element (106) extends helically about the longitudinal axis (304) and has an outer dimension (902). The outer dimension (902) increases in a distal direction (408) over a proximal section (904) of the fixation element (106), and the outer dimension (902) decreases in the distal direction (408) over a distal section (906) of the fixation element (106).

Disclosed herein is an implantable medical device (IMD) (100), and system (5) for denoising biological signals. The IMD (100) generates a biological signal representative of a physiologic parameter of a patient (3) and normally analyzes the biological signal to detect a characteristic of interest (COI) indicative of a pathophysiologic condition of the patient (3). The present technology denoises, when the IMD (100) is exposed to a noise causing condition, noisy biological signal segments of the biological signal generated while the IMD (100) is exposed to the noise causing condition using a denoising prediction model (400) to obtain denoised biological signal segments. The denoising prediction model (400) is trained to predict a denoised biological signal segment from a noisy biological signal segment. The denoised biological signal segments can then be analyzed to detect the COI indicative of the pathophysiologic condition of the patient (3).

A biostimulator transport system (300) includes a catheter shaft (402) having a catheter lumen (502) extending longitudinally to a distal catheter end (404). The biostimulator transport system (300) includes a docking cap (320) coupled to the catheter shaft (402) and having a docking cavity (512). A drive shaft (503) extends through the catheter lumen (502) to a distal shaft end (504). The biostimulator transport system (300) includes a motion converter (506) coupling the drive shaft (503) to the docking cap (320). The motion converter (506) converts longitudinal motion of the drive shaft (503) into rotational motion of the docking cap (320).

Described herein is a multi-chamber implantable LP system (100) comprising at least a first LP (102a, 102b) configured to be implanted in or on a first cardiac chamber, and a second LP (102b, 102a) configured to be implanted in or on a second cardiac chamber. For each cardiac event, of a plurality of cardiac events associated with the first cardiac chamber, the first LP (102a, 102b) is configured to determine for the cardiac event whether at least one of a plurality of predetermined conditions is satisfied. Additionally, the first LP (102a, 102b) is configured to abstain from transmitting a cardiac event message indicative of the cardiac event to the second LP (102b, 102a), or transmit the cardiac event message indicative of the cardiac event to the second LP (102b, 102a), based on whether there is a determination that at least one of the plurality of predetermined conditions is satisfied. Methods for use with such a multi-chamber implantable LP system (100) are also described herein.

A biostimulator transport system (302) includes a sheath (312) having a distal sheath end (314). The biostimulator transport system (302) includes a deployment tube (316) extending from the distal sheath end (314) to a distal tube end (318). The biostimulator transport system (302) includes an expandable structure (700) having a ventricle-shaped envelope (904) surrounding the deployment tube (316). The ventricle-shaped envelope (904) includes a front boundary (702) coupled to the distal tube end (318) and a rear boundary (704) coupled to the distal sheath end (314). The front boundary (702) and the rear boundary (704) are joined along one or more of a bottom edge (710) and lateral edges (802, 804).

An implantable biostimulator (104, 200, 302) has a housing (106, 212, 402, 502, 602), one or more fixation elements (210, 304, 418, 510, 610) at a distal end of the housing (106, 212, 402, 502, 602), and one or more electrode probes (208, 306, 406, 506). The housing (106, 212, 402, 502, 602)includes an electronics compartment containing pacing circuitry. The one or more electrode probes (208, 306, 406, 506)are coupled to the pacing circuitry. The one or more electrode probes (208, 306, 406, 506)are extendable from the distal end of the housing (106, 212, 402, 502, 602). The one or more electrode probes (208, 306, 406, 506) have depth control to a controlled depth of extension.

An apparatus comprises an accelerometer (125) and at least one processor (104). The accelerometer (125), alone or in combination with the at least one processor (104), used to determine an activity level of a patient and a posture of the patient. The at least one processor (104) configured to classify the patient as being asleep in response to both (i) the posture of the patient being recumbent or reclined for at least a sleep latency duration, and (ii) the activity level of the patient not exceeding an activity threshold for at least the sleep latency duration. The at least one processor (104) is also configured to, after the patient has been classified as being asleep, classify the patient as being awake in response to at least one of (iii) the posture of the patient being upright for at least an awake latency duration, or (iv) the activity level of the patient exceeding the activity threshold for at least the awake latency duration.

Devices (106, 109) and methods for improving conductive communication are described herein. One of the devices (106, 109) involved in the conductive communication can be an external device while the other device is an IMD, or both of the devices can be IMDs. In certain embodiments, conductive communication is performed using a first timing scheme that specifies when conductive communication pulses are transmitted relative to one or more cardiac events. A quality metric of the conductive communication is monitored, when the first timing scheme is being used to perform the conductive communication. In response to detecting the quality metric being below a corresponding threshold, when the first timing scheme is being used to perform the conductive communication, the invention changes to using a second timing scheme to perform the conductive communication.